טוען...
miR‐152‐5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7
A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ). Our study investigated the activity of FBXL7 and miR‐152‐5p in glioma. Levels of microRNA‐152‐5p (miR‐152‐5p) and the transcript and protein of FBXL7 were assessed by real‐time PCR and West...
שמור ב:
| הוצא לאור ב: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7176889/ https://ncbi.nlm.nih.gov/pubmed/32150671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15114 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|